Silver Book Fact

Use of antihypertensive therapies avoided an estimated $10.7 billion in 2002 direct medical costs as a result of fewer strokes. They also avoided an estimated $5.8 billion in 2002 direct medical costs as a result of fewer myocardial infarctions.

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Pioglitazone associated with relative risk reduction in recurrent stroke
    The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative…  
  • “Coronary heart disease spending has increased more than 40% over the past 15 years, and, as a whole, the health improvements have been well worth the costs. Over the entire…  
  • Satisfaction rates of heart valve disease patients with their treatment
     
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.